"V体育安卓版" High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma
- PMID: 18287132
- DOI: 10.3324/haematol.12184
High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma
Abstract
We describe the results of 37 myeloma patients who received bortezomib following reduced intensity allogeneic stem cell transplantation (RIC-allo-SCT). Grade 1-2 peripheral neuropathy (35%), mild thrombocytopenia (24%) and fatigue (19%) were the most frequent adverse events, while there was no worsening of graft-vs-host disease symptoms. Twenty-seven patients (73%; 95% CI, 59-87%) achieved an objective response. With a median follow-up of 9 months from bortezomib initiation, the estimate of overall survival was 65% at 18 months while this was significantly higher (p=0. 002) in the 27 patients achieving an objective response, suggesting that bortezomib is a safe and efficient option for myeloma patients after RIC-allo-SCT VSports手机版. .
Publication types
- VSports手机版 - Actions
MeSH terms
- V体育官网 - Actions
- Actions (VSports)
- "V体育ios版" Actions
- Actions (V体育平台登录)
- Actions (V体育官网入口)
- VSports - Actions
- "V体育平台登录" Actions
- "VSports注册入口" Actions
- "VSports最新版本" Actions
- Actions (V体育安卓版)
- V体育官网 - Actions
- Actions (VSports app下载)
- VSports在线直播 - Actions
- "VSports" Actions
- "V体育官网" Actions
Substances
- "VSports最新版本" Actions
- Actions (V体育2025版)
- "VSports" Actions
"VSports在线直播" LinkOut - more resources
- "VSports在线直播" Full Text Sources
- "V体育平台登录" Medical
 
        